[ TRANSACTION RECORD ]

GlaxoSmithKline Investment in GSK Aiolos Platform — 2024

VERIFIED VECTOR ID: 002217 · tx-313
M SOURCE NODE — FUNDER
GlaxoSmithKline
Healthcare United Kingdom
$140,000,000
EQUITY
09/01/2024
Q DESTINATION NODE — RECIPIENT
GSK Aiolos Platform
SPV United Kingdom
Amount (USD)
$140.0M
Flow Type
EQUITY
Transaction Date
09/01/2024
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity GlaxoSmithKline
AUM 100000
HQ Location United Kingdom
Sector Healthcare
Recipient Profile [ Q ]
Entity GSK Aiolos Platform
Entity Type SPV
Jurisdiction United Kingdom
Intelligence Note

GlaxoSmithKline agreed to acquire Aiolos Bio for 1.4 billion dollars to gain access to a long-acting respiratory treatment for asthma and specialty diseases. This transaction includes a strategic payment and future milestone commitments to support clinical development. This deal underscores GSK’s strategy to bolster its specialty medicines pipeline through targeted high-growth biotech acquisitions.

Σ
Primary Forensic Source https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-aiolos-bio/
✓ SOURCE LINKED